FDA orders new eye risk warnings for Ozempic, Zepbound

Posted on November 9, 2026

The FDA today informed patients and healthcare providers of a potential increased risk of a serious eye condition associated with the use of GLP-1 drugs for weight loss and diabetes.

See the original article at: Honolulu Star-Advertiser

<--- Like this post? You know what to do.

Comments are closed.